Uncategorized
Studies underway for sustained-release injectable anti-VEGFs for posterior diseases
CHICAGO – At the Ophthalmology Innovation Summit here, Amarpreet Sawhney, PhD, president and CEO of Ocular Therapeutix, discusses the company's evaluation of sustained-release injectable anti-VEGF drug depots for posterior eye diseases. Ocular Therapeutix's first product, ReSure Sealant, is now FDA-approved.